HHS has announced that GHK-Cu is expected to return to Category 1, which would restore compounding access for injectable formulations. BPC-157 On 23 July 2026, PCAC voted to recommend adding BPC-157 to the 503A Bulks List, against FDA staff, who had recommended against listing
Many patients notice improvement within 1-2 weeks, particularly reduced pain and improved mobility at injury sites
They are not intended for human consumption, clinical use, diagnostic use, therapeutic use, veterinary use, cosmetic use, or dietary supplement use
Oral Supplements: These are easy to take at home but require daily intake for consistent results
NAD+ precursors : Inhibits degradation for sustained effects
Skip the clinic visits and enjoy recovery support in the comfort of your home, office, or hotel